deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT01701310

IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia (IVICA)

An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy

Sponsor: National Institute for Health Research, United Kingdom

Updated 5 times since 2017 Last updated: Oct 27, 2016 Started: Apr 30, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Anemia and Colorectal Neoplasm, this trial is completed. The trial is conducted by National Institute for Health Research, United Kingdom and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute for Health Research, United Kingdom
  • Nottingham University Hospitals NHS Trust
Data source: Nottingham University Hospitals NHS Trust

For direct contact, visit the study record on ClinicalTrials.gov .